• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Gastroenterology Research and Practice >Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers
【2h】

Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers

机译：细胞周期调节剂细胞周期蛋白D1（CCND1）和细胞周期蛋白依赖性激酶抑制剂1B（CDKN1B / p27）在散发性胃癌中的预后重要性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. Gastric cancer is known for a notable variety in the course of the disease. Clinical factors, such as tumor stage, grade, and localization, are key in patient survival. It is expected that molecular factors such as somatic mutations and gene amplifications are also underlying tumor biological behavior and may serve as factors for prognosis estimation. Aim. The purpose of this study was to examine gene amplifications from a panel of genes to uncover potential prognostic marker candidates. Methods. A panel of gene amplifications including 71 genes was tested by multiplex ligation-dependent probe amplification (MLPA) technique in 76 gastric cancer samples from a Caucasian population. The correlation of gene amplification status with patient survival was determined by the Kaplan-Meier method. Results. The amplification of two cell cycle regulators, CCND1 and CDKN1B, was identified to have a negative prognostic role. The medial survival of patients with gastric cancer displaying amplification compared to patients without amplification was 192 versus 725 days for CCND1 (P = 0.0012) and 165 versus 611 days for CDKN1B (P = 0.0098). Conclusion. Gene amplifications of CCND1 and CDKN1B are potential candidates to serve as prognostic markers for the stratification of patients based on the estimate of survival in the management of gastric cancer patients.
机译：背景。胃癌以其在疾病过程中的显着变化而闻名。临床因素，例如肿瘤的分期，等级和位置，是患者生存的关键。预期诸如体细胞突变和基因扩增的分子因素也是肿瘤生物学行为的基础，并且可以用作预后评估的因素。目标。这项研究的目的是检查一组基因中的基因扩增，以发现潜在的预后标志物候选物。方法。通过多重连接依赖探针扩增（MLPA）技术，在来自白种人的76个胃癌样本中测试了包括71个基因在内的一组基因扩增。基因扩增状态与患者生存率的相关性通过Kaplan-Meier方法确定。结果。两种细胞周期调节剂CCND1和CDKN1B的扩增被确定具有负的预后作用。与未扩增的胃癌相比，胃癌患者的中位生存期为CCND1（192 = 725天，P = 0.0012）和CDKN1B为165天（611）（P = 0.0098）。结论。 CCND1和CDKN1B的基因扩增是潜在的候选基因，可根据胃癌患者管理中的生存率估计值对患者进行分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号